About this item:
368 Views | 667 Downloads
Author Notes:
Corresponding author: T. Adekambi, 954 Gatewood Rd, Atlanta, GA 30329, USA tadekam@emory.edu
We thank the patients for their participation in the study.
The content is solely the responsibility of the authors and does not necessarily represent the official views of ASM/UNESCO and Emory-CFAR.
Conflict of interest: None declared.
Subjects:
Research Funding:
This work was supported in part by an ASM-UNESCO VRP grant (to TA) and an Emory-CFAR03 developmental grant 00044613 (to TA) from P30AI050409 (to Emory University).
Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF
Abstract:
Drug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting Mycobacterium tuberculosis complex in sputum samples in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in Togo, where culturing M. tuberculosis complex from sputum samples is challenging
Copyright information:
Copyright © 2015 The Authors
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
